Latest Bg Medicine (BGMD) Headlines Small-Cap B
Post# of 7
Posted On: 03/13/2014 5:54:47 AM
Latest Bg Medicine (BGMD) Headlines
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease
GlobeNewswire - Wed Mar 12, 7:46AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) welcomed today an announcement by La Jolla Pharmaceutical Company (LJPC) on March 10, 2014 of positive top-line results of its randomized, placebo-controlled Phase 2 trial of the galectin-3 inhibitor compound GCS-100 in chronic kidney disease. The trial met its primary efficacy endpoint of improvement in kidney function, as well as key secondary endpoints including a statistically significant reduction in circulating levels of galectin-3, the molecular target of GCS-100, at the effective therapeutic dose, as measured using the BGM Galectin-3 Test.
BG Medicine Compliant With NASDAQ Listing Requirements
GlobeNewswire - Tue Mar 11, 5:02PM CDT
BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") today announced that it has received correspondence from The NASDAQ Stock Market LLC ("NASDAQ") confirming that the Company has evidenced compliance with the requirements for continued listing on The NASDAQ Capital Market. Accordingly, the NASDAQ compliance matter has been closed.
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers
GlobeNewswire - Mon Mar 10, 7:30AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian Consensus Document on Cardiac Biomarkers published by the Cardiological Society of India. [1] The Consensus Document on Cardiac Biomarkers reviews cardiac blood tests that are available for diagnosis and management in heart failure, and provides recommendations for physicians on their use and utility in caring for heart failure patients.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Can This Simple Test Predict Your Chances of Dying? If You Have Coronary Artery Disease, The Answer Is Yes, Say A Group of Renowned Scientists
Business Wire - Wed Feb 05, 7:59AM CST
Critical Diagnostics announced today the results of the LURIC study(1) of 1345 patients with stable coronary artery disease, established that, in a univariate analysis, patients with ST2 levels in the highest quartile exhibited a 2-fold increased risk of death. Results remained significant even in a fully adjusted model.
Heart Failure Study Proves Serial Testing of ST2 Can Help Improve Patient Care And Reduce Cardiovascular Events
Business Wire - Mon Feb 03, 7:59AM CST
Critical Diagnostics announced today that results of a Massachusetts General Hospital biomarker-guided therapy study of chronic heart failure patients with left ventricular systolic dysfunction followed over a 10-month period ("Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15 and Highly Sensitive Troponin T Measurement in Patients with Chronic Heart Failure") just published in the Journal of the American College of Cardiology's JACC: Heart Failure, demonstrated that of all biomarkers evaluated, only serial testing of ST2 enhanced prognostic information over baseline concentrations and predicted change in left ventricular function.
Why BG Medicine (BGMD) Is Up Today
at The Street - Tue Jan 28, 2:44PM CST
BG Medicine (BGMD) rises after the diagnostics company published results of a clinical research study that validated performance of the VIDAS Galectin-3, an automated assay developed by bioMerieux. The results noted that elevated galectin-3 levels in...
Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study
GlobeNewswire - Tue Jan 28, 7:31AM CST
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, welcomed today the publication of results of a clinical research study that demonstrate and validate the analytical and clinical performance of the automated VIDAS Galectin-3 assay that was developed by bioMerieux SA, a world leader in the field of in vitro diagnostics and one of BG Medicine's automation partners.
BG Medicine to Transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ Extension
GlobeNewswire - Mon Jan 27, 7:30AM CST
BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") announced today that the NASDAQ Listing Qualifications Panel (the "Panel") has granted the Company's request for the transfer of its listing from The NASDAQ Global Market to The NASDAQ Capital Market, which transfer will be effective with the open of business today. The Company's securities will continue to trade on NASDAQ under the symbol "BGMD."
Clinical Trial Results, Partnerships, and Reimbursement Rates - Research Report on Celldex, Centene, Enanta, Novartis, and BG Medicine
PR Newswire - Fri Dec 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Celldex Therapeutics, Inc. (NASDAQ: CLDX), Centene Corp. (NYSE: CNC), Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), Novartis AG (NYSE: NVS), and BG Medicine, Inc. (NASDAQ: BGMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Nasdaq stocks posting largest volume increases
AP - Wed Dec 11, 5:22PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Dec 11, 12:30PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test
GlobeNewswire - Tue Dec 10, 7:30AM CST
BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT(R) Code 82777) at the amount of a crosswalked test (analyte-specific CPT(R) Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.
HWAY and SulAmerica Join Forces, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 4:30PM CST
Healthways and SulAmerica enter into five year agreement but stocks continue to be down for HWAY.
Omnicare Raises Dividend, Approves Share Repurchase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 1:00PM CST
OCR believes in a consistent dividend payment policy with raises every year
Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure
GlobeNewswire - Tue Nov 19, 7:30AM CST
BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3 Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. [1]
Intrexon Corporation (XON) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 7:25AM CST
Intrexon was a big mover last session, with shares rising almost 9%.
Small-Cap Biotech on the Verge of a Breakout: ABIO
at The Street - Wed Mar 12, 12:43PM CDT
Here's how to trade Arca Biopharma.
BG Medicine Welcomes La Jolla Pharmaceutical Company's Announcement of Positive Top-Line Results of Phase 2 Clinical Trial of Novel Pharmaceutical Compound Targeting Galectin-3 in Chronic Kidney Disease
GlobeNewswire - Wed Mar 12, 7:46AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) welcomed today an announcement by La Jolla Pharmaceutical Company (LJPC) on March 10, 2014 of positive top-line results of its randomized, placebo-controlled Phase 2 trial of the galectin-3 inhibitor compound GCS-100 in chronic kidney disease. The trial met its primary efficacy endpoint of improvement in kidney function, as well as key secondary endpoints including a statistically significant reduction in circulating levels of galectin-3, the molecular target of GCS-100, at the effective therapeutic dose, as measured using the BGM Galectin-3 Test.
BG Medicine Compliant With NASDAQ Listing Requirements
GlobeNewswire - Tue Mar 11, 5:02PM CDT
BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") today announced that it has received correspondence from The NASDAQ Stock Market LLC ("NASDAQ") confirming that the Company has evidenced compliance with the requirements for continued listing on The NASDAQ Capital Market. Accordingly, the NASDAQ compliance matter has been closed.
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers
GlobeNewswire - Mon Mar 10, 7:30AM CDT
BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian Consensus Document on Cardiac Biomarkers published by the Cardiological Society of India. [1] The Consensus Document on Cardiac Biomarkers reviews cardiac blood tests that are available for diagnosis and management in heart failure, and provides recommendations for physicians on their use and utility in caring for heart failure patients.
5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.
Can This Simple Test Predict Your Chances of Dying? If You Have Coronary Artery Disease, The Answer Is Yes, Say A Group of Renowned Scientists
Business Wire - Wed Feb 05, 7:59AM CST
Critical Diagnostics announced today the results of the LURIC study(1) of 1345 patients with stable coronary artery disease, established that, in a univariate analysis, patients with ST2 levels in the highest quartile exhibited a 2-fold increased risk of death. Results remained significant even in a fully adjusted model.
Heart Failure Study Proves Serial Testing of ST2 Can Help Improve Patient Care And Reduce Cardiovascular Events
Business Wire - Mon Feb 03, 7:59AM CST
Critical Diagnostics announced today that results of a Massachusetts General Hospital biomarker-guided therapy study of chronic heart failure patients with left ventricular systolic dysfunction followed over a 10-month period ("Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15 and Highly Sensitive Troponin T Measurement in Patients with Chronic Heart Failure") just published in the Journal of the American College of Cardiology's JACC: Heart Failure, demonstrated that of all biomarkers evaluated, only serial testing of ST2 enhanced prognostic information over baseline concentrations and predicted change in left ventricular function.
Why BG Medicine (BGMD) Is Up Today
at The Street - Tue Jan 28, 2:44PM CST
BG Medicine (BGMD) rises after the diagnostics company published results of a clinical research study that validated performance of the VIDAS Galectin-3, an automated assay developed by bioMerieux. The results noted that elevated galectin-3 levels in...
Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study
GlobeNewswire - Tue Jan 28, 7:31AM CST
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test, welcomed today the publication of results of a clinical research study that demonstrate and validate the analytical and clinical performance of the automated VIDAS Galectin-3 assay that was developed by bioMerieux SA, a world leader in the field of in vitro diagnostics and one of BG Medicine's automation partners.
BG Medicine to Transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ Extension
GlobeNewswire - Mon Jan 27, 7:30AM CST
BG Medicine, Inc. (Nasdaq:BGMD) (the "Company") announced today that the NASDAQ Listing Qualifications Panel (the "Panel") has granted the Company's request for the transfer of its listing from The NASDAQ Global Market to The NASDAQ Capital Market, which transfer will be effective with the open of business today. The Company's securities will continue to trade on NASDAQ under the symbol "BGMD."
Clinical Trial Results, Partnerships, and Reimbursement Rates - Research Report on Celldex, Centene, Enanta, Novartis, and BG Medicine
PR Newswire - Fri Dec 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Celldex Therapeutics, Inc. (NASDAQ: CLDX), Centene Corp. (NYSE: CNC), Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), Novartis AG (NYSE: NVS), and BG Medicine, Inc. (NASDAQ: BGMD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Nasdaq stocks posting largest volume increases
AP - Wed Dec 11, 5:22PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Wed Dec 11, 12:30PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test
GlobeNewswire - Tue Dec 10, 7:30AM CST
BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT(R) Code 82777) at the amount of a crosswalked test (analyte-specific CPT(R) Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.
HWAY and SulAmerica Join Forces, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 4:30PM CST
Healthways and SulAmerica enter into five year agreement but stocks continue to be down for HWAY.
Omnicare Raises Dividend, Approves Share Repurchase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 09, 1:00PM CST
OCR believes in a consistent dividend payment policy with raises every year
Independent Multicenter Trial Demonstrates Utility of BGM Galectin-3(R) Test for Accurately Classifying Risk of Unplanned Hospital Readmissions and Adverse Outcomes in Patients With Heart Failure
GlobeNewswire - Tue Nov 19, 7:30AM CST
BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results of an independent multicenter clinical research trial in Europe that enrolled 419 heart failure patients and demonstrated that elevated levels of galectin-3 in blood, as measured using the BGM Galectin-3 Test, were significantly predictive of unplanned hospital readmissions and fatal events during the 12 month follow-up period of the trial. [1]
Intrexon Corporation (XON) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 18, 7:25AM CST
Intrexon was a big mover last session, with shares rising almost 9%.
(0)
(0)BG Medicine Inc. (BGMD) Stock Research Links
Scroll down for more posts ▼